Sign In
Buy ALT
$2.84
-0.140 (-4.70%)
At Close: Jul 31, 2026
Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript
12:03pm, Tuesday, 28'th Jul 2026
Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript
Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study
11:08am, Tuesday, 28'th Jul 2026
Altimmune Inc. (NASDAQ:ALT) has reported positive topline outcomes from its RECLAIM Phase 2 trial assessing pemvidutide in patients diagnosed with moderate to severe alcohol use disorder (AUD).
Altimmune's Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial
10:05am, Tuesday, 28'th Jul 2026
Altimmune NASDAQ: ALT reported positive top-line results from its Phase II RECLAIM trial evaluating pemvidutide in adults with moderate to severe alcohol use disorder, or AUD, with the company saying
Altimmune's drug meets main goal of mid-stage study for alcohol use disorder
07:08am, Tuesday, 28'th Jul 2026
Altimmune said on Tuesday its experimental drug met the main goal of a mid-stage trial to help people with alcohol use disorder.
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
07:00am, Tuesday, 28'th Jul 2026
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, in
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
10:16am, Tuesday, 07'th Jul 2026
Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed statistically significant MASH resolut
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
06:01am, Friday, 26'th Jun 2026
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
09:41am, Thursday, 25'th Jun 2026
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
12:31pm, Friday, 12'th Jun 2026
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
10:32am, Wednesday, 10'th Jun 2026
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Altimmune Sets Pemvidutide's Phase 3 MASH Playbook as AUD Data Near
09:05am, Wednesday, 10'th Jun 2026
Altimmune NASDAQ: ALT management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company's focus on pemvidutide, its lead metabolic and liver disease drug candidate
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
01:11pm, Monday, 08'th Jun 2026
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.
ALT and the Rise of Dual Agonists Targeting Liver Disease
01:11pm, Monday, 08'th Jun 2026
Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
12:55pm, Monday, 08'th Jun 2026
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
